- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01542879
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.
A research study on the diagnosis of spread of disease for children who have been diagnosed with solid tumors using a new whole body imaging technique and a new MR contrast agent (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG) scanning. The purpose of this study is to determine if newer imaging tests referred to as whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The advantage of the new imaging test is that it is associated with no or significantly reduced radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole body MR and PET/MR will be compared with that of the conventional, standard imaging studies for tumor detecting.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective: To compare the sensitivity, specificity and accuracy of WB-DW-MR scans (new technique) with 18F- FDG PET or 18F- FDG PET/CT or 18F- FDG PET/MR scans.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of a solid extra-cranial tumor like malignant lymphoma or malignant sarcoma and
- Scheduled for or completed a 18F-FDG-PET or 18F-FDG-PET/CT tumor staging procedure.
- There will be no restrictions on prior treatment.
- Very young children who need sedation or anesthesia will be excluded from the study.
- In this pediatric & adult study, the participant or parent/guardian is consented, and the patient when a minor is given an assent form and involved in the discussion as appropriate.
Exclusion Criteria:
- MR-incompatible metal implants,
- need of sedation or claustrophobia.
- Hemosiderosis/hemochromatosis (patients can still be included in 2nd branch without ferumoxytol)
- There will be restrictions regarding use of other Investigational Agents: Pt with iron-overload will not receive Ferumoxytol
- History of allergic reactions to similar compounds will be obtained and patients with a positive history of allergic reaction to iron compounds or other severe allergic reactions.will be excluded from the study.
- Pregnant women and fetuses.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: WB-DW-MR scan
simultaneous WB-DW-MR scan and 18-F FDG PET scan |
Other Names:
Other Names:
WB-DW-MR scans will be obtained on a 3T PET-MR system
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Receiver Operating Characteristic Curve (ROC) of Maximum Standard Uptake Value (SUV)
Time Frame: Baseline (day of scan), and 3 to 14 weeks post treatment (interval determined by tumor type and treatment protocol)
|
Clinical response prediction according to maximum Standard Uptake Value (SUV), assessed using receiver operating characteristic (ROC) curve analysis. Higher AUC values indicate better discrimination between responders and non-responders. |
Baseline (day of scan), and 3 to 14 weeks post treatment (interval determined by tumor type and treatment protocol)
|
|
Area Under the Receiver Operating Characteristic Curve (ROC) of Minimum Apparent Diffusion Coefficient (ADC)
Time Frame: Baseline (day of scan), and 3 to 14 weeks post treatment (interval determined by tumor type and treatment protocol)
|
Clinical response prediction according to minimum Apparent Diffusion Coefficient (ADC) values, assessed using receiver operating characteristic (ROC) curve analysis. The area under the ROC curve (AUC) measures the ability of minimum ADC values to distinguish responders from non-responders, with higher AUC values indicating better predictive performance. |
Baseline (day of scan), and 3 to 14 weeks post treatment (interval determined by tumor type and treatment protocol)
|
|
Sensitivity and Specificity of WB-DW-MR Compared to 18F-FDG PET/CT
Time Frame: 3 to 14 weeks post-treatment (interval determined by tumor type and treatment protocol)
|
Comparison of the sensitivity (true positive rate) and specificity (true negative rate) of WB-DW-MR scans versus standard 18F-FDG PET/CT scans for tumor detection and clinical response assessment, using imaging findings compared with the clinical reference standard (biopsy and/or follow-up imaging). |
3 to 14 weeks post-treatment (interval determined by tumor type and treatment protocol)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Signal-to-Noise Ratio as a Measure of Technical Optimization of Whole-Body Diffusion-Weighted MRI (WB-DW-MRI)
Time Frame: Baseline (day of scan)
|
Signal-to-noise ratio (SNR) was assessed to evaluate and optimize pulse sequence parameters and b-values for whole-body diffusion-weighted MRI. SNR was calculated from signal intensity measurements obtained from bone marrow metastases and normal bone marrow regions on diffusion-weighted MRI images. b50 images provide higher signal-to-noise ratio and visualization of tissue perfusion/anatomy, while b800 images emphasize restricted diffusion associated with malignancy and suppress background tissue signal. |
Baseline (day of scan)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Heike Daldrup-Link, Stanford University
Publications and helpful links
General Publications
- Theruvath AJ, Siedek F, Yerneni K, Muehe AM, Spunt SL, Pribnow A, Moseley M, Lu Y, Zhao Q, Gulaka P, Chaudhari A, Daldrup-Link HE. Validation of Deep Learning-based Augmentation for Reduced 18F-FDG Dose for PET/MRI in Children and Young Adults with Lymphoma. Radiol Artif Intell. 2021 Oct 6;3(6):e200232. doi: 10.1148/ryai.2021200232. eCollection 2021 Nov.
- Theruvath AJ, Siedek F, Muehe AM, Garcia-Diaz J, Kirchner J, Martin O, Link MP, Spunt S, Pribnow A, Rosenberg J, Herrmann K, Gatidis S, Schafer JF, Moseley M, Umutlu L, Daldrup-Link HE. Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. Radiology. 2020 Jul;296(1):143-151. doi: 10.1148/radiol.2020192508. Epub 2020 May 5.
- Klenk C, Gawande R, Uslu L, Khurana A, Qiu D, Quon A, Donig J, Rosenberg J, Luna-Fineman S, Moseley M, Daldrup-Link HE. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol. 2014 Mar;15(3):275-85. doi: 10.1016/S1470-2045(14)70021-X. Epub 2014 Feb 19.
- Rashidi A, Baratto L, Theruvath AJ, Greene EB, Jayapal P, Hawk KE, Lu R, Seekins J, Spunt SL, Pribnow A, Daldrup-Link HE. Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI. Radiol Imaging Cancer. 2023 Mar;5(2):e220080. doi: 10.1148/rycan.220080.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-20221
- NCI-2012-015321 (Other Identifier: National Cancer Institute: Clinical Trials Reporting Program)
- 1R01CA269231-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.